[DOI] [PMC free article] [PubMed] [Google Scholar] 91.Alfaris N, Waldrop S, Johnson V, et al
Angiogenesis and regenerative medicine investigations
The STEP trials for semaglutide 2.4 mg (Wegovy) showed: Average weight loss of approximately 15% of body weight over 68 weeks One-third of participants lost 20% or more of body weight Significant reductions in waist circumference, blood pressure, and cardiovascular risk markers The SURMOUNT trials for tirzepatide (Zepbound) showed even more impressive results: Average weight loss of 20-25% at the highest dose (15 mg) over 72 weeks More than half of participants lost 20% or more of body weight Significant improvements in type 2 diabetes markers, blood pressure, and lipid profiles The head-to-head comparison is clear
Bottom line: Annual cost on compounded semaglutide cash-pay: Mochi $2,736-$4,176
Diabetes Research and Clinical Practice, 161 , 108087